ABSTRACT

The present invention provides O-glycan $\alpha 2,8$ -sialyltransferase which has novel substrate specificity and substrate selectivity, and β -galactoside $\alpha 2,6$ -sialyltransferase which has novel action and substrate specificity. The sialyltransferase of the present invention can be used as a medicament for suppression of cancer metastasis, prevention of virus infection, suppression of inflammatory response, or activation of neural cells.